Nadine Peters, chief legal officer of COTA, shares her journey to leadership in health data privacy law and policy recommendations for the Biden Administration on achieving health equity through data use and education.
The final day of the conference, Friday, December 11, includes a panel on precision medicine investment trends, a look at clinical trial design innovation and the life sciences track of our Pitch Perfect startup contest. Register now!
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
A panel at MedCity CONVERGE in July will discuss the challenges preventing precision medicine from reaching its full potential and how we can overcome them.
IQVIA led the round, and other participants included EW Healthcare Partners and Memorial Sloan Kettering Cancer Center. The startup's Cota Nodal Address (CNA) system is a classification system that puts patients in different categories based on specific attributes.
The two New York City-based organizations have partnered on an initiative aimed at precision oncology research and treatment. By leveraging Cota's classification system, Memorial Sloan Kettering will improve patient care and accelerate research efforts.
Boston Millennia Partners was among the investors in Cota, which builds technology to measure patient outcomes from specific treatment protocols.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
A big data cancer platform that helps docs with reimbursement issues and the business end of personalized medicine has received a new cash infusion. New Jersey-based startup COTA, shortened from Cancer Outcomes Tracking & Analysis, closed a $3.7 million Series A tranche from Horizon Healthcare Services for its platform that delivers clinical data and cost analysis for cancer […]